These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12051560)

  • 1. The Society of Toxicologic Pathology's recommendations on statistical analysis of rodent carcinogenicity studies.
    Toxicol Pathol; 2002; 30(3):415-8. PubMed ID: 12051560
    [No Abstract]   [Full Text] [Related]  

  • 2. The Society of Toxicologic Pathology's position on statistical methods for rodent carcinogenicity studies.
    Morton D
    Toxicol Pathol; 2001; 29(6):670-2. PubMed ID: 11794383
    [No Abstract]   [Full Text] [Related]  

  • 3. Statistical methods for carcinogenicity studies.
    Toxicol Pathol; 2002; 30(3):403-14. PubMed ID: 12051559
    [No Abstract]   [Full Text] [Related]  

  • 4. Progress report on the guidance for industry for statistical aspects of the design, analysis, and interpretation of chronic rodent carcinogenicity studies of pharmaceuticals.
    Lin KK
    J Biopharm Stat; 2000 Nov; 10(4):481-501. PubMed ID: 11104389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International Conference on Harmonisation: guidance on testing for carcinogenicity of pharmaceuticals. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Feb; 63(35):8983-6. PubMed ID: 12269370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Conference on Harmonisation; proposed change to rodent carcinogenicity testing of pharmaceuticals; request for comments. Notice; request for comments.
    Food and Drug Administration, HHS
    Fed Regist; 2013 Mar; 78(52):16681-4. PubMed ID: 23530289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panel discussion: alternative mouse models for carcinogenicity assessment.
    French JE; Leblanc B; Long GG; Morton D; Storer R; Leighton J; Swenberg J; Tsuda H
    Toxicol Pathol; 2010 Jan; 38(1):72-5. PubMed ID: 19884653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory Forum.
    Peden WM
    Toxicol Pathol; 2016 Dec; 44(8):1069-1071. PubMed ID: 27753636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproductive toxicology guidelines: comparison and application.
    Beltrame D; Mazué G
    Ann Ist Super Sanita; 1993; 29(1):3-14. PubMed ID: 8129269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the pathologist in GLP studies.
    Weber K; Hailey JR; Mann PC; Seaton M; Funk KA
    Toxicol Pathol; 2014 Jan; 42(1):275. PubMed ID: 24436040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 0 trials: a platform for drug development?
    Lancet; 2009 Jul; 374(9685):176. PubMed ID: 19616703
    [No Abstract]   [Full Text] [Related]  

  • 12. Excess mortality in two-year rodent carcinogenicity studies.
    Roth A; Kadyszewski E; Geffray B; Paulissen J; Weaver RJ
    Toxicol Pathol; 2007 Dec; 35(7):1040-3. PubMed ID: 18098048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinogenicity of psychotropic drugs: A systematic review of US Food and Drug Administration-required preclinical in vivo studies.
    Amerio A; Gálvez JF; Odone A; Dalley SA; Ghaemi SN
    Aust N Z J Psychiatry; 2015 Aug; 49(8):686-96. PubMed ID: 25916799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of test procedures for multidose animal carcinogenicity assays under competing risks.
    Graves TS
    J Biopharm Stat; 1994 Nov; 4(3):289-320. PubMed ID: 7881450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The do's and don'ts of preclinical development.
    Graffeo A
    Biotechnology (N Y); 1994 Sep; 12(9):865-9. PubMed ID: 7765226
    [No Abstract]   [Full Text] [Related]  

  • 16. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles.
    Rajaram L; Roy SK; Skerjanec A
    Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biostatistical issues in the design and analysis of animal carcinogenicity experiments.
    Portier CJ
    Environ Health Perspect; 1994 Jan; 102 Suppl 1(Suppl 1):5-8. PubMed ID: 8187725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing for carcinogenicity of pharmaceuticals.
    Usui T; Masuda H
    J Toxicol Sci; 1996 Dec; 21(5):475-8. PubMed ID: 9035057
    [No Abstract]   [Full Text] [Related]  

  • 19. Further analysis of Ames-negative rodent carcinogens that are only genotoxic in mammalian cells in vitro at concentrations exceeding 1 mM, including retesting of compounds of concern.
    Kirkland D; Fowler P
    Mutagenesis; 2010 Nov; 25(6):539-53. PubMed ID: 20720197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs.
    Jacobs A
    Toxicol Lett; 2009 Apr; 186(1):32-5. PubMed ID: 18809476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.